Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults.

A comparison was made of antibody responses generated to live varicella (Oka/Merck) vaccine (Varivax) produced during three different manufacturing campaigns to evaluate the quality of the antibody responses and demonstrate consistency of the manufacturing process. Anti-varicella zoster virus (VZV) antibody titers were measured by an enhanced neutralization assay and VZV glycoprotein-based enzyme-linked immunosorbent assay (gpELISA). For sera taken from children who had received one dose of vaccine an excellent linear concordance in titers was observed between the two assays. Sera from adults who had received two doses demonstrated continuing increased neutralization at high gpELISA titers. The immunogenicity measured by the two assays demonstrates that the overall performance of the vaccine was very similar over the three production series.

Assays for antibodies to varicella-zoster virus.

Anti-varicella-zoster virus serum antibody assays and their use in vaccine development are described. Of particular interest are FAMA and neutralization assays and the gpELISA. These and other assays are compared and summarized in terms of characteristics including biologic relevance, sensitivity, specificity, and suitability for different laboratory and clinical applications.

Combined use of complement and anti-immunoglobulin in an enhanced neutralization assay for antibodies to varicella-zoster virus.

An enhanced neutralization assay was developed to permit the sensitive, specific, and reproducible measurement of antibodies to varicella-zoster virus (VZV). Optimal neutralization was achieved using a combination of guinea pig complement (C') and rabbit anti-human IgG. This provided 625-, 160- and 13- to 64-fold increases in dilution endpoints of human post-zoster serum, varicella-zoster immune globulin and representative sera from recipients of live attenuated varicella vaccine, respectively, above those measured in the absence of C' and anti-IgG. The specificity of the assay was shown by the absorption of serum neutralization capacity with VZV-specific antigen and the lack of concordance between antibody titers to VZV with those to either herpes simplex virus type-2 or cytomegalovirus. The antibody status of recipients of live attenuated varicella vaccine was established from the amount of neutralizing activity produced at a single optimal serum dilution.

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.

Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX; Merck Sharp and Dohme Research Laboratories) containing approximately 1000 to 1625 plaque-forming units/dose during clinical trials conducted from 1987 to 1989. Clinical follow-up of vaccinees revealed that 2.1 and 2.4% of vaccinees developed modified cases of varicella in the first and second years, respectively, after vaccination. Most of those who developed varicella postvaccination had an attenuated illness, characterized by fewer lesions and a lower incidence of fever (greater than or equal to 100 degrees F, oral) than after natural infection. The likelihood of developing varicella postvaccination decreased (P less than 0.0001) as the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer increased. In addition the number of lesions in these cases tended to decrease (P = 0.07 for Year 1 and P = 0.02 for Year 2) as the 6-week glycoprotein-based enzyme-linked immunosorbent assay titer increased. Thus the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer can be used as a surrogate marker for protection from natural disease.

Further evaluation of a live hepatitis A vaccine in marmosets.

Live, attenuated F' hepatitis A vaccine virus was studied in vivo in Saguinus labiatus marmosets for possible reversion to virulence, for possible establishment of persistent infection and for its capacity as a parenterally administered vaccine to induce immunity to oral infection. Serial transmission of the virus in S. labiatus, using infectious stool extracts for the second and third passages, produced no evidence of reversion of the F' vaccine virus to virulence. Monitoring for live HAV in stools over a 135-day period post-inoculation of marmosets with the F' vaccine revealed no evidence of persistent infection. Vaccinated animals were also shown to be resistant to infection on challenge by the oral route as well as by the previously demonstrated parenteral route.

A simplified multiwell plate assay for the measurement of hepatitis A virus infectivity.

A standardized multiwell plate assay (MWPA) was developed to provide a simple in situ measurement of hepatitis A virus (HAV) infectivity titers. Following attachment (4 h, 35 degrees C) of serial 10-fold dilutions of HAV strain CR326 F (variant F') to confluent MRC-5 monolayers in 24-well plates, cultures were overlaid with maintenance medium and incubated for 35 days at 35 degrees C with weekly medium replacement. Cells were fixed with 90% acetone and HAV antigen was quantitated by reaction with a radio-iodinated anti-HAV serum. Measurement of virus infectivity was based on the amounts of specifically bound and eluted radiolabelled antibody. Virus titers (50% tissue culture infectious doses/ml, TCID50/ml) were calculated using the method of Reed & Muench (Am J Hyg. 1938; 27: 493-497), with wells producing cpm values greater than 2.1-times that of uninoculated controls considered positive. The use of a virus standard provided an estimate of the test variability (+/- 5% in Log10 TCID50 units). The MWPA offers a significant savings in time and reagents, and is proposed as a standard method for the simple and reliable measurement of the potency of HAV vaccine preparations.

A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus.

A simplified hepatitis A virus (HAV) antigen-reduction neutralization assay (HAVARNA) was developed to permit the measurement of biologically active antibodies in recipients of candidate HAV vaccines. Degrees of neutralization were measured from the reduction in the amount of HAV antigen synthesized by 7-10 days after infection of MRC-5 (fetal human diploid lung) cell cultures. Sera producing a greater than or equal to 50% reduction in viral infectivity were scored as neutralizing. The assay was applied to demonstrate serum HAV neutralizing activity in 10 of 10 and 9 of 10 recipients of 10(7) and 10(6) TCID50 doses, respectively, of the Merck CR326F (F' variant) live attenuated vaccine. The dilution end points of selected sera ranged from 1:10 to 1:640. The dilution end point of the World Health Organization reference globulin no. 1 was 1:530,000 (0.2 mlU/ml of HAV antibody). The HAVARNA provided a rapid, sensitive, and reproducible means to measure neutralizing antibodies to HAV.

Antibody assays suitable for assessing immune responses to live varicella vaccine.

An enzyme-linked immunosorbent assay for antibodies to varicella-zoster virus (VZV), using purified viral glycoproteins as antigen (gpELISA), was compared with other assays for measuring vaccine-induced antibody responses. The gpELISA was more sensitive than conventional assays, proved highly specific for VZV and agreed well with an assay for neutralizing antibody activity. It was successfully applied to large-scale testing of live varicella vaccine in humans.

Enhancement of varicella-zoster virus plaquing efficiency with an agarose overlay medium.

The infectivity titers of varicella-zoster virus (VZV) are routinely estimated by plaque production in cell culture. In this report, we show that plaque counts for VZV (strain Oka/Merck), in MRC-5 cell cultures, are significantly enhanced (54% average enhancement) by the use of an agarose overlay medium, as compared to a fluid overlay medium. Evidence also is presented that less variability (P less than 0.05) in plaque counts occurs with the use of an agarose overlay medium.

Characterization of octyl glucoside-solubilized cell membrane receptors for binding measles virus.

Optimum conditions were determined for solubilizing cell membrane receptors for binding measles virus (MV). Evidence for specific receptors was shown from the saturability of MV binding to intact Vero cells or African Green Monkey erythrocytes (MRBCs). Receptors, solubilized from Vero cells and MRBC with 1.5% octyl glucoside, inhibited MV attachment, infectivity, and hemagglutination activities. Extracts from chicken erythrocytes, which did not bind MV, were inactive in all assays. MV binding activity in Vero or MRBC extracts was stable to heating (100 degrees, 10 min) or neuraminidase treatment, but was inactivated by a range of proteases, including chymotrypsin, and bound to lentil and pea lectin agaroses, to indicate a glycoprotein component.

Mice immunized with measles virus develop antibodies to a cell surface receptor for binding virus.

Mice were immunized with measles virus to determine whether an auto-anti-idiotypic antireceptor response could be generated as a probe for measles virus receptors. Mice initially responded to viral antigens (days 11 to 18) and subsequently developed antibodies to a putative measles virus receptor (peak at day 30 to 35) by three criteria: the sera (1) agglutinated erythrocytes which virus agglutinates, (2) reacted with Vero cells, and (3) inhibited virus attachment to Vero cells. Additionally, select sera inhibited virus infection of Vero cells. The cell-reactive activity was identified as immunoglobulin G antibody and was neutralized by sera reacting with virus (idiotype). The application of this anti-idiotypic antibody to identify measles virus-binding sites on Vero cells was revealed by the ability of sera to immunoprecipitate 20- and 30.5-kilodalton proteins from metabolically labeled ([35S]methionine) Vero cells.

Selective inhibition of WSN influenza virus haemolysis by pea lectin.

The capacity of lectins to inhibit viral haemolysis of chicken erythrocytes was tested, to evaluate the role of carbohydrate in the fusion reaction. Pretreatment of cells with pea lectin provided a 70% to 85% haemolysis inhibition with WSN influenza virus, but only 10% to 14% with PR8 influenza virus. Pea lectin did not detectably bind to virus, nor did it inhibit virus binding to cells, but it did inhibit WSN influenza virus elution. Additionally, pea lectin was active against Sendai virus and B/Lee influenza virus, but inactive against Newcastle disease virus. Haemolysis by WSN and PR8 influenza viruses was unaffected in cells pretreated with concanavalin A, peanut, wheatgerm or soybean lectins. A possible role of cellular carbohydrate in virus-cell fusion is discussed.

Resistance of a measles virus mutant to fusion inhibitory oligopeptides is not associated with mutations in the fusion peptide.

The nucleotide sequence and predicted amino acid sequence has been obtained for the fusion (F) protein gene of the R93 strain of measles virus and compared to that of the parental strain, Edmonston B. The R93 strain is a mutant measles virus which is able to grow and induce cell fusion in the presence of the fusion inhibiting oligopeptide, Z-D-Phe-L-Phe-L-(NO2)Arg (SV4814). Primer extension sequencing on isolated R93 mRNA demonstrated the presence of three nucleotide changes leading to three amino acid changes, none of which are in the hydrophobic NH2-terminal region of the F1 polypeptide.

Purification of a HeLa cell receptor protein for group B coxsackieviruses.

Coxsackievirus B3 (CB3) firmly attaches to HeLa cells, forming a specific complex between the virus and its receptor on the cell surface. We extracted this virus-receptor complex (VRC) with the detergents sodium deoxycholate and Triton X-100. The VRC was identified by its sedimentation coefficient (140S), which was less than that of virions (155S). Formation of the VRC from cell lysates and 3H-CB3 occurred with the same specificity as did attachment of virions to cells, in that its formation was blocked by unlabeled CB3 but not by poliovirus. The VRC was purified 30,000-fold by differential and sucrose gradient centrifugation. Iodination with Na125I revealed that the purified VRC consisted of the normal CB3 proteins and one additional protein (RP-a) with an approximate molecular weight of 49,500. RP-a was eluted from the VRC and was shown to rebind with CB3 and CB1 virions but not with poliovirus type 1. We propose that Rp-a is a protein in the plasma membrane receptor complex which is responsible for the specific recognition and binding of the group B coxsackieviruses.

Properties of the deoxycholate-solubilized HeLa cell plasma membrane receptor for binding group B coxsackieviruses.

Physical and chemical properties of deoxycholate-solubilized HeLa cell plasma membrane receptors for binding group B coxsackieviruses were determined. Receptors eluted from Sepharose 4B with an apparent molecular weight of 275,000 and sedimented with an S value of between 14.7 and 4.9 and a buoyant density of 1.06 to 1.10 g/cm3. Virus-binding activity was destroyed after treatment with proteases, glycosidases, and periodate but was unaffected by lipases or reducing or alkylating agents. Additionally, lectins, including concanavalin A, adsorbed receptors and inhibited virus attachment. The composite data suggested that glycoprotein is an integral part of the receptors for binding virus.